Anti-p40 - DeltaNp63 antibody [BC28] (ab172731)
Key features and details
- Mouse monoclonal [BC28] to p40 - DeltaNp63
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-p40 - DeltaNp63 antibody [BC28]
See all p40 - DeltaNp63 primary antibodies -
Description
Mouse monoclonal [BC28] to p40 - DeltaNp63 -
Host species
Mouse -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Cow -
Immunogen
Synthetic peptide corresponding to Human p40 - DeltaNp63 aa 5-17.
Sequence:ENNAQTQFSEPQY
Database link: Q9H3D4 -
Positive control
- IHC-P: Human lung squamous cell carcinoma.
-
General notes
This product was changed from ascites to tissue culture supernatant on 20/07/17. The following lots are from ascites and are still in stock as of [20/07/17] – [GR311007, GR322490]. Lot numbers higher than [GR322490] will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot. Store at +4°C. Do Not Freeze. -
Storage buffer
Preservative: 0.09% Sodium azide
Constituent: bovine serum albumin -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
BC28 -
Isotype
IgG1 -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab172731 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (3) |
1/50 - 1/100. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
|
Notes |
---|
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol. |
Target
-
Relevance
Differentiating between lung adenocarcinoma and squamous cell carcinoma is an important distinction with therapeutic implications. Although the most frequently recommended squamous marker p63 is extremely sensitive, it suffers from low specificity due to its reactivity in a substantial proportion of lung adenocarcinomas and other tumor types, particularly lymphomas. p40 is a relatively unknown marker that recognizes ?Np63-a p63 isoform suggested to be highly specific for squamous/basal cells. p40 is equivalent to p63 in sensitivity for squamous cell carcinoma, but it is markedly superior to p63 in specificity, which eliminates a potential pitfall of misinterpreting a p63-positive adenocarcinoma or unsuspected lymphoma as squamous cell carcinoma. These findings strongly support the routine use of p40 in place of p63 for the diagnosis of pulmonary squamous cell carcinoma. -
Database links
- SwissProt: Q9H3D4 Human
-
Alternative names
- 40 kDa Rab9 effector protein antibody
- 8430412M01Rik antibody
- 9530020d24rik antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab172731 has been referenced in 12 publications.
- Kuroda N et al. Effectiveness of radiation therapy on brain invasion by human papillomavirus-related multiphenotypic sinonasal carcinoma: A case report. Neuropathology 42:45-51 (2022). PubMed: 34933397
- Kawachi H et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy 13:799-806 (2021). PubMed: 34030451
- Hattori T et al. Elevated expression of protease-activated receptor 1 via ?Np63 down-regulation contributes to nodal metastasis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 50:163-170 (2021). PubMed: 32536459
- Ekpo P et al. Characterization of limbal explant sites: Optimization of stem cell outgrowth in in vitro culture. PLoS One 15:e0233075 (2020). PubMed: 32407348
- Ota T et al. Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified. J Cancer Res Clin Oncol 145:2495-2506 (2019). PubMed: 31494736